Since at high doses, Met did not show further increased inhibition on lung cancer cell proliferation, we investigated whether the cells survived Met treatment remained sensitive to cytotoxicity of a receptor tyrosine-kinase inhibitor (TKI) erlotinib (Erlo) therefore benefit from a combined treatment. This evidence concerns the gene NTRK1 and lung cancer.